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Introduction: Severe hemophilia and subsequent hemophilic arthropathy result in joint pain 
and impaired health-related quality of life (HRQoL). Assessment of HRQoL in persons with 
hemophilia (PWH), including underlying factors that drive HRQoL differences, is important in 
determining health care resource allocation and in making individualized clinical decisions.
Aim: To examine potential associations between HRQoL, pain interference, and self-reported 
arthritis and age, employment, activity, bleed frequency, and hemophilia treatment center and 
health care professional utilization.
Methods: PWH (age $18 years) from ten countries completed a 5-point Likert scale on pain 
interference over the previous 4 weeks, the EQ-5D-3L scale (mobility, usual activities, self-
care, pain/discomfort, anxiety/depression) including a health-related visual analog scale (0–100, 
coded as an 11-point categorical response).
Results: Pain interference (extreme/a lot) was higher in PWH aged .40 years (31%) compared 
to those aged 31–40 years (27%) or #30 years (21%). In an analysis of eight countries with 
home treatment, PWH who reported EQ-5D mobility issues were less likely to be employed 
(53% vs 79%, with no mobility issues). Median annual bleed frequency increased with worsen-
ing EQ-5D pain or discomfort. The percentage of PWH with inhibitors reporting visual analog 
scale scores of 80–90–100 was lower (20%) than those without inhibitors (34%). Median 
bleed frequency increased with pain. Globally, nurse and social worker involvement increased 
with disability and pain; physiotherapist utilization was moderate regardless of the extent of 
disability or pain.
Conclusion: Increased disability and pain were associated with increased age, lower 
employment, higher reported bleed frequency, and lower HRQoL.
Keywords: hemophilia, quality of life, HERO, pain
Introduction
Severe congenital hemophilia A (HA) and hemophilia B (HB) are associated with 
various types of bleeding, of which 70%–80% of bleeds are hemarthroses (joint 
bleeds).1 According to a retrospective data analysis of patients with severe hemophilia 
in the UK, the most common joints affected in adult persons with hemophilia (PWH) 
were the ankle (60.0%), knee (12.9%), and elbow (14.3%), although bleeding also 
occurred in the hips, shoulders, wrist, hands, and feet.2 Recurrent joint bleeding can 
result in acute and subsequent chronic hemophilic synovitis, leading to irreversible 
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damage to joint cartilage and bone.1,3 Hemarthrosis, synovitis, 
and hemophilic arthropathy ultimately result in acute and 
persistent joint pain1,3 as well as progressive limitations in 
range of motion.4 Pain and functional impairment impact 
the patient’s employment, relationships, daily activities, and 
perceived quality of life.1
Measuring the health-related quality of life (HRQoL) of 
PWH, as well as assessing what affects a patient’s HRQoL, 
is important to inform policy decisions regarding health 
care resource utilization and in individual clinical decision-
making.5 As treatment strategies evolve, interest has grown 
in measuring the HRQoL in PWH.5–7 Strategies to measure 
HRQoL have included standardized (eg, EQ-5D-3L, SF-36) 
and novel disease-specific instruments (Haemo-A-QoL, 
HaemoQoL, Hemophilia Activities List).8–10 The standard 
of care in developed countries is the comprehensive care 
model at hemophilia treatment centers (HTCs), and as part 
of that model, nurses, social workers, and physiotherapists, 
in part, spend time addressing psychosocial issues impacting 
HRQoL, including pain and functional impairment.
The Hemophilia Experiences, Results and Opportuni-
ties (HERO) study aimed to provide a large-scale global 
assessment of psychosocial issues (including employment, 
comorbidities, pain, functional impairment, relationships, 
HRQoL) affecting adults and children with hemophilia and 
their families in ten countries, as well as to assess treatment 
parameters and HTC/health care practitioner (HCP) utiliza-
tion. The demographics and impact on employment and 
recreational activities have been described by Forsyth et al11 
and issues relating to treatment and impact on relationships 
have also been discussed by Nugent et al12 and Cassis et al13 
respectively.
The aim of this analysis is to describe the overall quality 
of life in adult respondents based on covariates identified in 
the primary analysis of HERO and to focus on patient HRQoL 
assessed by EQ-5D-3L, EQ-5D health-related visual analog 
scale (VAS), and categorical measure of pain interference in 
the previous 4 weeks. Additional post hoc analysis of covari-
ates, including associations between EQ-5D and pain inter-
ference with employment, bleed frequency, and HTC/HCP 
utilization, included the eight countries (excludes Algeria 
and People’s Republic of China) that predominantly reported 
home infusion treatment. This study adds to the current 
understanding of HRQoL in adult PWH by providing a large 
multinational assessment of how multiple patient variables 
may affect overall quality of life. These results may be impor-
tant for informing health policy decisions and may suggest 
opportunities to improve comprehensive patient care.
Methods
A detailed methodology of HERO has been described 
elsewhere.11 Briefly, the study used two online Web-
based questionnaires (one for PWH and one for parents of 
affected children), each consisting of more than 100 items that 
included multiple choice questions and rating scales. In gen-
eral, participants were recruited through national hemophilia 
organizations via email and Web pages. To address country-
specific needs in Algeria, where access to the Internet is limited, 
participants were allowed to complete a paper version of the 
survey that was circulated by mail. In addition, an agency panel 
was used to collect the data in France. The original design of 
HERO was to evaluate a total of ~600 PWH ($18 years old) 
and 600 parents responding on behalf of their oldest affected 
child (,18 years old) from 12 countries, with the goal of 
having 50 PWH and 50 parents from each country. Ethical 
approvals were secured in ten participating countries (Alge-
ria, Argentina, Canada, People’s Republic of China, France, 
Germany, Italy, Spain, the UK, and the US), and informed 
consent was obtained where required. To ensure that the global 
enrollment targets were met, the 200 subjects from Japan and 
Brazil, and other unmet recruitment targets, were reallocated 
to larger countries (specifically the US and People’s Republic 
of China).11 The final number of survey respondents for each 
country were as follows: Algeria (n=50), Argentina (n=50), 
Canada (n=30), People’s Republic of China (n=110), France 
(n=50), Germany (n=60), Italy (n=43), Spain (n=41), the UK 
(n=52), and the US (n=189).
The current analyses reported here include adult 
males $18 years of age with HA or HB, with or without 
inhibitors. To define a population with moderate-to-severe 
hemophilia, adult PWH were required to have either 
1) received regular replacement therapy or 2) had at least 
one spontaneous bleed into one or more joints within the 
previous 12 months. Inclusion criteria did not differ between 
countries. All adult PWH were asked to report comorbidities, 
including self-reported arthritis, and to complete an EQ-5D-3L 
(mobility, usual activities, self-care, pain/discomfort, anxiety/
depression)14 and an EQ-5D VAS (0–100, coded electronically 
as an 11-point categorical response based upon the nearest 
value). Based on EQ-5D-3L responses, an EQ-5D index was 
derived using the methodology of Shaw et al.15 Treatment regi-
men (on-demand, prophylaxis, or on-demand with situational 
prophylaxis) was provided by each PWH/parent; however, the 
type (primary, secondary, situational), duration, and timing of 
current prophylaxis treatment were not collected.
Statistical analyses were primarily descriptive and correla-
tive in nature, as the study was not powered for determinations 
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of statistical significance. Primary analysis of HERO data 
was based on all adult PWH in the ten participating countries 
with cross tabulations by individual country. Subsequent 
post hoc analyses that included HTC utilization and HCP 
involvement in management were based on the results of 
eight countries. To minimize the impact of additional utiliza-
tion around acute bleed treatment (eg, factor infusions) at the 
HTC reported by most of the respondents from Algeria and 
People’s Republic of China, the eight countries analyzed were 
those that employed predominantly home infusion treatment. 
The same post hoc analysis was completed separately for 
PWH respondents from the US, who accounted for a large 
percentage (37%) of patients in the eight-country analysis. In 
addition, there are published values for HRQoL (specifically 
EQ-5D index) for the general US population, which allows 
for comparison to the HERO hemophilia population.
Results
Patient demographics
Detailed patient demographics, including cross tabulations 
by country, have been published previously.11 Among the 
675 adult PWH from ten countries who completed the 
survey, the median (interquartile range, IQR) age was 36 
(28–45) years with an overall range of 18–86 years. For 
all adult PWH, the majority (74%) reported HA, with 13% 
reporting HB and 13% reporting hemophilia with inhibi-
tors. Of the 91 patients reporting hemophilia with inhibitors 
(median age, 34 years), 45 were from the US (median age, 
33 years). The most common reported comorbidities asso-
ciated with hemophilia were self-reported arthritis (49%), 
hepatitis C virus (43%), and/or human immunodeficiency 
virus (18%). Excluding patients from Algeria and People’s 
Republic of China, the median (IQR) age for the eight-
country subset was 38 (30–48) years, and for the US, it was 35 
(28–41) years. Other demographic parameters were similar to 
those reported above for the subset of eight countries included 
in post hoc analyses, including the US (Table S1).
Pain interference
Overall, 89% of adult PWH reported that they experienced 
pain that interfered with activities in the previous 4 weeks; 
26% of adult PWH reported that in the past 4 weeks, pain 
interfered with their daily life “extremely” or “quite a lot”. 
The percentage of adults .40 years old (31%) reporting 
“extreme” or “quite a lot” of pain interference was higher 
than that of adults aged 31–40 years (27%) or #30 years 
(21%). The percentage of adults reporting “extreme” or 
“quite a lot” of pain interference was also higher in those with 
self-reported arthritis (35% vs 15% without) (Figure 1A). 
Similar results were seen in patients from the US, with a 
slightly higher percentage (41%) aged .40 years and a lower 
percentage (9%) aged #30 years, reporting “extreme” or 
“quite a lot” of pain interference (Figure 1B).
Of patients with inhibitors, 18% reported “extreme” or 
“quite a lot” of pain interference compared to 27% of patients 
with HA and 29% of patients with HB. This may be driven 
by the fact that half (45/91, 49%) of the patients with inhibi-
tors were from the US,12 were younger, and reported a high 
frequency of prophylactic use (22/45 [49%]); only 2% of US 
patients with inhibitors reported “extreme” or “quite a lot” 
of pain interference, compared to 27% of patients with HA 
and 18% of patients with HB. In addition, the global inhibi-
tor population was slightly younger (median age, 34 years) 
than patients with HA or HB (median age, 36 years for each; 
Table 1). The extent of pain interference by country is shown 
in Figure 1C.
Adults were most likely to report that they experience pain 
only when a bleed occurs (42%), while 21% reported persis-
tent pain and 29% reported persistent pain that worsens when 
they have a bleed; 8% reported they did not know when their 
pain occurred. Those who were employed were more likely to 
report pain only when a bleed occurs (eg, no persistent pain) 
than those who were not employed (48% vs 31%). PWH with 
self-reported arthritis were more likely to report persistent pain 
(pain all the time or pain all the time that worsens when they 
have a bleed) than those without (62% vs 34%).
eQ-5D components, index, and VAs
More than half (59%) the adult patients reported problems 
with mobility (Table 1). Adults on prophylaxis (type, dura-
tion, timing, and extent during lifetime not documented) 
reported more issues with mobility (64% vs 52% on-demand). 
Most patients (75%) reported moderate or extreme pain or 
discomfort (Tables 1 and 2). Adults currently on prophylaxis 
reported more pain or discomfort (80%) than those treated 
on-demand (67%). Adults with inhibitors reported slightly 
more pain or discomfort (81%) than those with HA (74%) 
or HB (72%). EQ-5D component scores varied between 
countries (Table 2).
The EQ-5D index for all adult patients who participated 
in HERO, tabulated by hemophilia type and treatment regi-
men, is shown in Table 1. Treatment was categorized based 
on current treatment and may not be reflective of any/all 
prior treatment since diagnosis or the extent to which the 
patients received prophylaxis during their life. In the global 
population, the mean EQ-5D index was higher (which 
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reflects a better health state) in adults treated on-demand 
(0.7505) or on prophylaxis (0.7466) than those treated on-
demand plus short-term prophylaxis (0.7178). In the US, 
adult respondents currently treated on-demand had a higher 
EQ-5D index (0.8184) than those who were on prophylaxis 
(0.7521) or treated on-demand plus short-term prophylaxis 
(0.7026). In the global population, EQ-5D index was similar 
for those with HA and HB (0.7453 and 0.7407), but lower 
in PWH with inhibitors (0.7075). In the slightly younger US 
respondent population with a greater percentage of inhibitor 
patients on prophylaxis and without pain interference, EQ-5D 
index was similar in patients with HA, HB, or hemophilia 
with inhibitors (0.7598, 0.7645, and 0.7675, respectively). 
EQ-5D index is also shown by country in Table 2. Compared 
to the normative US population, patients with hemophilia 
(both globally and in the US) have a lower EQ-5D index 
score for all age groups and exhibit a decrease in index with 
advancing age (Table 3).
In total, 32% of adults reported “good” VAS health 
scores (reported categorically as 80–90–100). The percent-
age of adults with inhibitors reporting “good” VAS health 
scores was lower, compared to those without inhibitors, for 
both the global (20% vs 34% without) (Figure 2A) and US 
(24% vs 48% without) populations (Figure 2B). Those who 
were employed were more likely to report good scores than 
those who were not employed (36% vs 20%). PWH without 
self-reported arthritis also more often reported good scores 
than those with self-reported arthritis (44% vs 23%).
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Figure 1 extent to which pain has interfered with daily life over the past 4 weeks.
Notes: statistical analyses were primarily descriptive and correlative in nature. (A) global herO population, (B) Us herO population, and (C) By country.
Abbreviations: herO, hemophilia experiences, results and Opportunities; w/o, without.
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Associations with employment
Overall, 80% reported that hemophilia had a negative impact 
on employment. Fewer PWH with inhibitors reported no 
negative impact (5% vs 21% without).11 Most adults were 
employed full- or part-time or self-employed (60%), with few 
unemployed and looking for a job (8%); 13% were unable 
to work due to long-term disability.11
In the post hoc analysis of eight countries (included 
only those with predominantly home infusion treatment), 
adult PWH who reported EQ-5D mobility issues were less 
likely to be employed full- or part-time or self-employed 
(53% vs 79% with no mobility issues) (Figure 3A); this 
was true of adult PWH in the US analysis (55% vs 85% 
with no mobility issues) (Figure 3A). Adults who reported 
extreme EQ-5D pain/discomfort were less likely to be 
employed (31% vs 84% with no pain/discomfort; 35% vs 
93%, respectively in US adults) (Figure 3A). Adults who 
reported a pain interference rating of a lot/extreme pain or 
discomfort were less likely to be employed (41% employed) 
compared to those reporting none/a little bit (73%) or 
moderate (67%) pain interference. US adults also reported 
lower employment with increasing pain interference (a lot/
extreme, 38%; moderate, 73%; and none/a little bit, 88%) 
(Figure 3A).
Table 1 eQ-5D index by hemophilia type and treatment regimen for adult global and Us herO populations
Total Hemophilia type Treatment regimen
HA HB HWI OD PPX OD + STP
Global HERO population, n 675 498 86 91 289 207 146
Median age, years 36 36 36 34 36 36 36
Any reported limitations, n (%)a
Mobility 398 (59) 294 (59) 53 (62) 51 (56) 151 (52) 132 (64) 92 (63)
self-care 136 (20) 94 (19) 18 (21) 24 (26) 61 (21) 32 (15) 33 (23)
Usual activities 315 (47) 219 (44) 44 (51) 52 (58) 130 (44) 92 (43) 79 (54)
Pain or discomfort 503 (75) 367 (74) 62 (72) 74 (81) 194 (67) 164 (80) 128 (81)
Anxiety or depression 313 (46) 231 (46) 40 (47) 42 (46) 141 (49) 88 (43) 68 (47)
eQ-5D index 0.7396 0.7453 0.7407 0.7075 0.7505 0.7466 0.7178
US HERO population, n 189 111 33 45 66 73 49
Median age, years 35 35 36 33 36 32 34
Any reported limitations, n (%)a
Mobility 81 (43) 54 (49) 16 (48) 11 (24) 16 (24) 37 (51) 27 (55)
self-care 26 (14) 17 (15) 5 (15) 4 (7) 7 (11) 11 (15) 8 (16)
Usual activities 81 (43) 44 (40) 15 (45) 22 (49) 21 (32) 33 (45) 27 (55)
Pain or discomfort 135 (71) 79 (71) 22 (67) 34 (76) 41 (62) 52 (71) 41 (84)
Anxiety or depression 82 (43) 53 (48) 13 (39) 16 (36) 20 (30) 33 (45) 28 (57)
eQ-5D index 0.7625 0.7598 0.7645 0.7675 0.8184 0.7521 0.7026
Notes: statistical analyses were primarily descriptive and correlative in nature. aThe EQ-5D questionnaire consists of five questions with three answer categories (no impact, 
some impact, and severe impact). The category “any reported limitations” includes “some impact” and “severe impact”.
Abbreviations: hA, hemophilia A; hB, hemophilia B; herO, hemophilia experiences, results and Opportunities; hWi, hemophilia with inhibitors; OD, on-demand; OD + 
sTP, on-demand with situational prophylaxis; PPX, prophylaxis.
Table 2 eQ-5D index by country
Country
Algeria 
(n=50)
Argentina 
(n=50)
Canada 
(n=30)
People’s 
Republic of 
China  
(n=110)
France 
(n=50)
Germany 
(n=60)
Italy 
(n=43)
Spain 
(n=41)
UK 
(n=52)
US 
(n=189)
Median age, years 29 35 38 29 40 43 45 34 47 35
Any reported limitations, n (%)
Mobility 27 (54) 27 (54) 22 (73) 79 (72) 29 (58) 33 (55) 27 (63) 30 (73) 43 (83) 81 (43)
self-care 19 (38) 4 (8) 1 (3) 30 (27) 8 (16) 6 (10) 4 (9) 16 (39) 22 (42) 26 (14)
Usual activities 24 (48) 14 (28) 18 (60) 64 (58) 23 (46) 19 (32) 15 (35) 22 (54) 35 (67) 81 (43)
Pain or discomfort 40 (80) 33 (66) 24 (80) 72 (65) 41 (82) 43 (77) 43 (84) 32 (78) 44 (85) 135 (71)
Anxiety or depression 30 (60) 19 (38) 12 (40) 66 (60) 22 (44) 21 (35) 26 (60) 16 (39) 19 (37) 82 (43)
eQ-5D index 0.7013 0.7736 0.7359 0.7092 0.7834 0.7749 0.7420 0.7832 0.6648 0.7625
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Associations with bleeding frequency
Spontaneous bleeding was reported by most PWH with HA 
(76%) or HB (67%) and was higher in those with inhibitors 
(93%).11 Median (IQR) number of bleeds in the past year was 
7 (2–20) with a nonnormal distribution due to outliers with 
higher bleeding rates.11 In the eight countries with home treat-
ment, adults who reported any EQ-5D mobility issues reported 
a higher median bleed frequency (7) in the past year compared 
to those with no issues (2) (Figure 3B). This was also seen in 
US patients (15 with issues vs 6 with no issues) (Figure 3B).
Median bleed frequency in the past year increased with 
worsening EQ-5D pain or discomfort for both those countries 
with home treatment (extreme, 18; moderate, 6; none, 2; 
Figure 3B) and US (a lot/extreme, 24; moderate, 9; none, 2; 
Figure 3B) respondents. Adults who self-reported arthritis 
and those with increased pain interference also reported 
higher bleed frequencies (Figure 3B).
Associations with hcP utilization
Adults from all ten countries were most likely to report 
that a hematologist (89%) or hemophilia nurse (51%) was 
involved in the management of their hemophilia. Fewer 
adult PWH reported involvement of a physiotherapist (35%), 
general practitioner (22%), social worker (16%), counselor 
or psychologist (12%), or complementary therapist (eg, acu-
puncture, massage; 5%). Availability of each of these HCP 
specialists at the HTC level was not documented, and the term 
“management” was left to the patient’s interpretation.
In the eight-country analysis, adults who reported mod-
erate EQ-5D mobility issues were slightly more likely than 
those with no mobility issues to report nurse involvement 
(56% vs 48%) and social worker involvement (22% vs 
17%) in their hemophilia management; physiotherapist 
Table 3 eQ-5D index by age group
Age, 
years
US norms Global HERO 
population
US HERO 
population
Study 126,a Study 227,b N Mean (SD) N Mean (SD)
,35 n/A 0.89 278 0.766 (0.197) 94 0.770 (0.181)
35–44 0.89 0.87 153 0.744 (0.174) 61 0.806 (0.173)
45–54 0.88 0.87 106 0.702 (0.199) 20 0.699 (0.243)
55–64 0.86 0.84 36 0.678 (0.200) 10 0.600 (0.219)
65–74 0.87 0.86 16 0.707 (0.166) 4 0.651 (0.268)
75–89 0.85 n/A 2 0.568 (0.297) 0 n/A
Notes: statistical analyses were primarily descriptive and correlative in nature. 
an=1,641 males. bn=2,722 total population, number of males not specified.
Abbreviations: herO, hemophilia experiences, results and Opportunities; n/A, 
not applicable; sD, standard deviation.
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involvement did not vary (38% vs 36%; Figure 4). In the 
US respondents, those reporting moderate EQ-5D mobility 
issues reported less frequent involvement of physiotherapists 
in management (33%) than those without mobility issues 
(45%). US adults who reported any EQ-5D mobility issues 
were more likely than those with no mobility issues to report 
nurse involvement (83% vs 69%) and social worker involve-
ment (56% vs 33%) in their hemophilia management.
Similarly, adults who reported EQ-5D extreme pain 
or discomfort were more likely than those with no pain 
or discomfort to report nurse involvement (67% vs 49%, 
respectively) and social worker involvement (32% vs 14%, 
respectively); this did not change as much for physiotherapist 
involvement (44% vs 39%, respectively; Figure 4). Adult 
PWH who self-reported arthritis were more likely than those 
who did not report to identify nurse involvement (61% vs 
45%, respectively), social worker involvement (27% vs 
14%, respectively), and physiotherapist involvement (41% 
vs 34%, respectively; Figure 4). For US respondents, those 
with extreme EQ-5D pain and discomfort reported lower 
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physiotherapist involvement (41%) than those without pain 
and discomfort (54%); adults who reported extreme EQ-5D 
pain or discomfort were no more likely than those with no 
pain or discomfort to report nurse involvement (77% vs 78%, 
respectively) and were more likely to report social worker 
involvement (64% vs 26%) in their hemophilia management. 
US adults with self-reported arthritis reported lower phys-
iotherapist involvement (30%) than those without arthritis 
(48%) but identified more nurse involvement (80% vs 70%, 
respectively) and social worker involvement (52% vs 34%, 
respectively; Figure 4).
Discussion
This analysis of the HERO study data identifies important 
associations between HRQoL and various patient- and 
disease-related characteristics. It has previously been 
reported that patients with hemophilia complicated by inhibi-
tors experience a lower HRQoL.16,17 This finding is supported 
by the current analysis of the global (ten-country) popula-
tion of adult PWH respondents in HERO, in which patients 
with inhibitors reported a lower EQ-5D index (0.7075) than 
those with HA (0.7453) or HB (0.7407) and greater pain 
interference compared to patients without inhibitors. Other 
studies have also found the severity of disease to affect 
HRQoL and EQ-5D index. In a UK study, 67 PWH with 
severe hemophilia were shown to exhibit a lower median 
EQ-5D index score than 101 PWH with moderate/mild 
hemophilia (0.66 and 0.85, respectively);18 the low HRQoL 
of patients with severe hemophilia is also supported by a 
similar study of 72 adults with severe HA or HB, which 
reported a mean EQ-5D utility of 0.64.18 Furthermore, the 
Hemophilia Utilization Group Study Va (HUGS-Va) found 
physical component scores (PCS-12, component of the Short 
Form-12 Health Survey) to be decreased with increasing 
severity of disease.19 EQ-5D index values reported in the 
current study, which included patients with moderate-to-
severe hemophilia (mean, 0.7396; 0.7625 in the US), are 
therefore expected to be lower than for patients with mild/
moderate hemophilia.
Consideration must be given to the home country of 
each participant when assessing patient-reported HRQoL. 
The perceptions, descriptions, open discussions, and con-
trol of pain are culture and country specific;20 therefore, 
PWH from one country may have a different perception of 
their pain than PWH from other countries. Ethnicity and 
culture also affect the expression or verbal description of 
pain and may influence the way in which patients respond 
to pain assessment questions.21 This may account for some 
of the variability in pain interference between countries 
participating in HERO.
An additional patient variable that may influence HRQoL 
is history of a prophylactic treatment regimen, as suggested 
by multiple published studies.22–24 Significant differences in 
HRQoL have been found between Swedish patients, who 
have had access to prophylaxis since the 1970s, and patients 
from Ireland, the UK, and France, where prophylaxis was not 
routine until the 1990s; patients from Sweden spent more of 
their life on prophylaxis (P#0.05) and had the lowest annual 
bleed rates, a lower presence of target joints (P#0.001), 
and the highest EQ-5D utility value (0.93) compared with 
those from the other countries (0.68–0.76).22 Furthermore, 
when pooled across countries, those on lifetime prophy-
laxis (100%) had higher mean EQ-5D utility values (0.88) 
compared with those treated only in part with prophylaxis 
(0.77–0.79) or treated exclusively on-demand (0.72).22 
Important effects of prophylaxis on HRQoL are also sup-
ported by a recent multinational survey of 116 adults, which 
found EQ-5D index scores to increase with time spent on 
prophylaxis; patients always treated on-demand had a lower 
EQ-5D index (0.619) than those who spent ,50% of their 
life on prophylaxis (0.755), those who spent $50% of their 
life on prophylaxis (0.812), and those who were always 
on prophylaxis (0.866).23 Prophylaxis with recombinant 
activated factor VII (rFVIIa) has also been shown to improve 
HRQoL in patients with inhibitors; patients who participated 
in a prospective trial and received rFVIIa prophylactically 
for 3 months followed by 3 months of postprophylaxis 
(treated on-demand) showed improvements in EQ-5D 
index (mean, 0.68) compared to the preprophylaxis period 
(mean, 0.65).24
Bleed type and the number of bleeding episodes may 
also affect EQ-5D index and pain. In the current analysis, 
increased bleed frequency was associated with worsen-
ing EQ-5D and more pain interference. PWH treated with 
on-demand plus short-term prophylaxis had the lowest 
EQ-5D index and, as indicated in previous reports of HERO 
study data, had the highest median annual bleed frequency 
(20) compared to those treated on-demand (5) or with 
prophylaxis (5).12 Important effects of bleeds on HRQoL are 
also supported by data from the Dosing Observational Study 
in Hemophilia (DOSE), a diary study that evaluated the use 
of bypassing agents, with a focus on the use of rFVIIa in the 
home setting, and captured EQ-5D on a daily basis.25 PWH 
with inhibitors in DOSE reported significantly lower EQ-5D 
index scores on bleed days (mean ± standard deviation: 
0.64±0.23) compared to nonbleed days (0.84±0.16, P,0.001 
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vs nonbleeding days), indicating significantly reduced 
HRQoL associated with each bleeding episode.25 Addition-
ally, results from an international survey of adult PWH found 
that those treated on-demand had a worse EQ-5D index and 
were more likely to report more than 30 bleeds in the past 
year (61%) compared to those who spent ,50% of their life 
on prophylaxis (3%) or $50% of their life on prophylaxis 
(0%) or were always on prophylaxis (0%).23 HRQoL may 
also be considerably worse in PWH who experience more 
pain; results from the international survey showed that PWH 
with the least exposure to prophylactic treatment (associated 
with the worst reported HRQoL) were most likely to report 
daily pain.23 Furthermore, results from the HUGS-Va study 
showed HRQoL to be worse in patients who reported more 
pain, as assessed by PCS-12 scores.19
Previous analysis of the HERO study data indicated that 
adult PWH reported a median of 2 HTC visits in the past 
year; this was lower in the US population (median, 1).12 
Even though US PWH are visiting HTCs less, they reported 
more nurse (75% vs 51%) and social worker (43% vs 16%) 
involvement in the management of their hemophilia than 
the global population.12 In the current analysis of the global 
population, nurse and social worker involvement was more 
commonly reported in association with worsening EQ-5D 
and increased pain interference. Nurse involvement in the 
US varied by EQ-5D disability and pain interference. Social 
worker involvement in the US was associated with worsen-
ing EQ-5D and increased pain interference, as also seen in 
the global population. Across all adult PWH respondents, 
the amount of physiotherapist involvement was similar in 
the US (40%) compared to the global population (35%).12 
Globally, physiotherapist involvement increased with 
worsening EQ-5D and increased pain interference. In the 
US respondents, physiotherapist involvement was more 
frequently reported in association with better EQ-5D and less 
pain interference. Physiotherapist involvement in manage-
ment of hemophilia may be lower than nurse involvement in 
PWH for a variety of reasons. One reason may be a lack of 
availability and utilization of physiotherapists at an individual 
HTC or the distance of the HTC from the PWH’s home, as 
PWH/parents may not want to travel a great distance for 
physiotherapist appointments. In the US, it may be due to 
lack of insurance coverage for physiotherapists (for both 
comprehensive care visits and subsequent therapy) or the 
lack of full-time physiotherapists at each HTC. However, 
the HERO study did not specifically ask PWH which HCPs 
were readily available or they had seen at their HTC, but 
rather those who were involved in the management of 
hemophilia. Therefore, the overall low involvement of social 
workers and physiotherapists may be variably due to either 
narrow perceptions of what constitutes management (eg, 
doctor who prescribes treatment) or a true lack of availability 
at individual HTCs within each country.
Conclusion
As a patient-reported study, HERO gives a unique perspec-
tive on life with hemophilia for adult PWH. Increased dis-
ability and pain were associated with increased age, lower 
employment, higher reported bleed frequency, and lower 
HRQoL. Adults who reported experiencing more pain were 
more likely to report suffering from what they self-reported 
as arthritis and to have more issues with mobility. Results 
suggest that more can be done to achieve the standard of 
true comprehensive care, including greater participation of 
physiotherapists, social workers, and counselors across HTCs 
with varied resources.
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Table S1 Demographics of the eight-country post hoc analysis patient population
Global PWH  
(n=675)
PWH eight-country 
subanalysis (n=515)
Age of respondents, years
Median 36 38
iQr 28–45 30–48
hemophilia type, % n=675 n=515
hemophilia A 74 71
hemophilia B 13 13
hemophilia A or B with inhibitors 13 16
Treatment regimen, % n=648 n=501
On-demand 45 36
Prophylaxis 32 41
On-demand + short-term prophylaxis 23 23
Note: statistical analyses were primarily descriptive and correlative in nature.
Abbreviations: iQr, interquartile range; PWh, patients with hemophilia.
